natgillin/translations-raw huggingface dataset:
In the subgroup aged &gt; 65 years the percentage of vaccinees with rSBA titres ≥ 128 at one month post- vaccination ranged from 90% (group A) to 97% (group Y).
U podskupini ispitanika starijih od 65 godina, postotak cijepljenika koji su mjesec dana nakon cijepljenja imali rSBA titre ≥ 128 kretao se u rasponu od 90% (grupa A) do 97% (grupa Y).
In the subgroup aged &gt; 65 years the percentage of vaccinees with rSBA titres ≥ 128 at one month post-vaccination ranged from 90% (group A) to 97% (group Y).
U podskupini ispitanika starijih od 65 godina, postotak cijepljenika koji su mjesec dana nakon cijepljenja imali rSBA titre ≥ 128 kretao se u rasponu od 90% (grupa A) do 97% (grupa Y).
In the subgroup of patients with HR ≥ 75 bpm (n=4150), a greater reduction was observed in the primary composite endpoint of 24 % (hazard ratio: 0.76, 95%CI [0.68;0.85] – p &lt; 0.0001) and for other secondary endpoints, including all cause death (hazard ratio: 0.83, 95%CI [0.72;0.96] – p=0.0109) and CV death (hazard ratio: 0.83, 95%CI [0.71;0.97] – p=0.0166).
U podskupini bolesnika sa srčanom frekvencijom ≥ 75/min (n=4 150), zabilježeno je izraženije smanjenje primarnog kompozitnog ishoda od 24% (omjer hazarda (HR): 0,76, 95%CI [0,68;0,85] – p &lt; 0,0001) kao i za ostale sekundarne ishode, uključujući smrt zbog svih uzroka (omjer hazarda (HR): 0,83, 95%CI [0.72;0.96] – p=0,0109) i smrt zbog kardiovaskularnih uzroka (omjer hazarda (HR): 0,83, 95%CI [0.71;0.97] – p=0,0166).
In the subgroup of patients with recent symptom onset ( &lt; 3 years) the clinical benefit of ChondroCelect over microfracture was significantly larger, confirming the results at 36 months after treatment.
U podskupini bolesnika s nedavnom pojavom simptoma ( &lt; 3 godine) klinička korist liječenjem lijekom ChondroCelect naspram liječenja mikrofrakturom bila je značajno veća, što potvrđuje rezultate opažene 36 mjeseci nakon liječenja.
In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, Aclasta increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36% ; p &lt; 0.001).
U subpopulaciji bolesnika koji su primali glukokortikosteroide dulje od 3 mjeseca prije randomizacije, Aclasta je povećala BMD lumbalne kralježnice za 4,06% naspram 2,71% za risedronat (srednja vrijednost razlike: 1,36%; p &lt; 0,001).
In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, zoledronic acid increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36% ; p &lt; 0.001).
U subpopulaciji bolesnika koji su primali glukokortikoide dulje od 3 mjeseca prije randomizacije zoledronatna kiselina povisila je BMD lumbalne kralježnice za 4,06% u usporedbi sa 2,71% pri primjeni risedronata (srednja vrijednost razlike: 1,36%; p &lt; 0,001).
In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, zoledronic acid increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36%; p &lt; 0.001).
U subpopulaciji bolesnika koji su primali glukokortikoide dulje od 3 mjeseca prije randomizacije zoledronatna kiselina povisila je BMD lumbalne kralježnice za 4,06% u usporedbi sa 2,71% pri primjeni risedronata (srednja vrijednost razlike: 1,36%; p &lt; 0,001).
In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, Aclasta increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96% ; p &lt; 0.001).
U subpopulaciji bolesnika koji su primali glukokortikosteroide 3 mjeseca ili kraće prije randomizacije, Aclasta je povećala BMD lumbalne kralježnice za 2,60% naspram 0,64% za risedronat (srednja razlika 1,96%; p &lt; 0,001).
In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, zoledronic acid increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96% ; p &lt; 0.001).
U subpopulaciji bolesnika koji su primali glukokortikoide 3 mjeseca ili kraće prije randomizacije zoledronatna kiselina povećala je BMD lumbalne kralježnice za 2,60% u odnosu na 0,64% pri primjeni risedronata (srednja razlika: 1,96%; p &lt; 0,001).
In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, zoledronic acid increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96%; p &lt; 0.001).
U subpopulaciji bolesnika koji su primali glukokortikoide 3 mjeseca ili kraće prije randomizacije zoledronatna kiselina povećala je BMD lumbalne kralježnice za 2,60% u odnosu na 0,64% pri primjeni risedronata (srednja razlika: 1,96%; p &lt; 0,001).
In the subset of patients requiring courses of OCS treatment for management of their asthma exacerbation, reslizumab was shown to reduce the frequency of asthma exacerbations by 56% (p &lt; 0.0001) and 60% (p &lt; 0.0001) in Study I and Study II, respectively.
U podskupini bolesnika kojima su bile potrebne terapijske kure peroralnim kortikosteroidima zbog liječenja egzacerbacije astme pokazalo se da je reslizumab smanjio učestalost egzacerbacija astme za 56 % (p &lt; 0,0001) u Ispitivanju I i 60 % (p &lt; 0,0001) u Ispitivanju II.
In the subset of patients with genotype 1 infection and low viral load ( &lt; 600,000 IU/ml) who become HCV-RNA negative at treatment week 4 and remain HCV-RNA negative at week 24, the treatment could either be stopped after this 24 week treatment course or pursued for an additional 24 weeks (i.e. overall 48 weeks treatment duration).
U podskupini bolesnika s infekcijom genotipa 1 i malim virusnim opterećenjem ( &lt; 600 000 IU/ml) koji postanu HCV-RNK negativni u 4. tjednu liječenja i ostanu HCV-RNK negativni u 24. tjednu, liječenje se može ili prekinuti nakon ta 24 tjedna liječenja ili nastaviti tijekom dodatna 24 tjedna (tj. ukupno trajanje liječenja od 48 tjedana).
In the substudy of study VI, patients who had achieved remission at 2 years (DAS 28 ESR &lt; 2.6) and after at least 1 year of treatment with abatacept in Study VI were eligible to enter a substudy.
Bolesnici koji su nakon 2 godine postigli remisiju (DAS28 ESR [sedimentacija eritrocita] &lt; 2,6) i najmanje godinu dana su bili liječeni abataceptom u Ispitivanju VI, mogli su se uključiti u podispitivanje u sklopu Ispitivanja VI.
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000)).
U donjoj tablici navedene su sve medicinski značajne nuspojave koje su se javile u kliničkim ispitivanjima s incidencijom većom nego kod placeba razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000)).
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000).
U donjoj tablici navedene su sve medicinski značajne nuspojave koje su se javile u kliničkim ispitivanjima s incidencijom većom nego kod placeba razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1 000).
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000).
U donjoj tablici navedene su sve medicinski značajne nuspojave koje su se javile u kliničkim ispitivanjima s incidencijom većom nego kod placeba razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000)).
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000).
U donjoj tablici navedene su sve medicinski značajne nuspojave, koje su se javile u kliničkim ispitivanjima s učestalošću većom nego kod placeba, razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1 000).
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000)..
U donjoj tablici navedene su sve medicinski značajne nuspojave koje su se javile u kliničkim ispitivanjima s incidencijom većom nego kod placeba razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000)).
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency [very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000)].
U donjoj tablici navedene su sve medicinski značajne nuspojave, koje su se javile u kliničkim ispitivanjima s učestalošću većom nego kod placeba, razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000).
In the table below, adverse reactions reported in all clinical studies and in the worldwide post-marketing experience for which a reasonable causal relationship exists are listed by MedDRA system organ class and frequency: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from available data).
U sljedećoj su tablici nuspojave zabilježene u svim kliničkim ispitivanjima nakon stavljanja lijeka u promet u svijetu za koje postoji razuman uzročno-posljedični odnos navedene prema MedDRA klasifikaciji organskih sustava i učestalosti: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000), nepoznato (se ne može procijeniti iz dostupnih podataka).
In the table below, adverse reactions reported in the double-blind period of the Phase 3 study are listed by MedDRA system organ class and frequency: very common (≥ 1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
U donjoj su tablici navedene nuspojave, prijavljene u dvostruko slijepom razdoblju ispitivanja faze III, u skladu s MedDRA klasifikacijom organskih sustava i učestalosti: vrlo često (≥ 1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10.000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10.000).
In the tenofovir disoproxil fumarate treatment arm, 7% of patients discontinued treatment due to an adverse event; 9% of patients experienced a confirmed increase in serum creatinine of ≥ 0.5 mg/dl or confirmed serum phosphate of &lt; 2 mg/dl through week 48; there were no statistically significant differences between the combined tenofovir-containing arms and the entecavir arm.
U skupini koja je primala tenofovirdizoproksilfumarat, 7% pacijenata prekinulo je liječenje zbog jedne od nuspojava, 9% pacijenata imalo je dokazano povećanje serumskog kreatinina od &gt; 0,5 mg/dl ili dokazano povećanje serumskih fosfata od &lt; 2 mg/dl kroz 48 tjedana; nije bilo statistički značajnih razlika između skupina koje su primale kombinirano liječenje tenofovirdizoproksilom i skupine na entekaviru.
In the third study in 1009 patients with mild or moderate asthma (n=537) and moderate or severe COPD (n=472) the incidence of FEV1 reduction &gt; 15% from baseline was 1.1% and 2.9% in patients with asthma (p=0.15) and 4.2% and 5.4% in patients with COPD (p=0.58) following Rapiscan and placebo dosing, respectively.
U trećem ispitivanju na 1009 bolesnika s blagom do umjerenom astmom (n=537) i umjerenom do teškom KOBP (n=472) incidencija smanjenja FEV1 &gt; 15% od polaznih vrijednosti bila je 1,1% odnosno 2,9% u bolesnika s astmom (p=0,15) i 4,2% odnosno 5,4% u bolesnika s KOBP (p=0,58) nakon primjene doze Rapiscana odnosno placeba.
In the three smallest of these 20 subgroups, the point estimate of the hazard ratio exceeded 1.25; i.e., in subjects with no prior nephrectomy (n=186, HR=1.403, 95 % CI (0.955, 2.061)), baseline LDH &gt; 1.5 x ULN (n=68, HR=1.72, 95 % CI (0.943, 3.139)), and MSKCC: poor risk (n=119, HR=1.472, 95 % CI (0.937, 2.313)).
U tri najmanje podskupine od njih 20, procjena omjera hazarda bila je viša od 1,25; tj. u ispitanika bez ranije nefrektomije (n=186, HR=1,403, 95% CI (0,955; 2,061)), početne vrijednosti LDH &gt; 1,5 x iznad gornje granice normale (n=68, HR=1,72, 95% CI (0,943; 3,139)) i MSKCC: nizak rizik (n=119, HR=1,472, 95% CI (0,937;
In the two placebo-controlled phase III trials, tests on thyroid stimulating hormone (TSH) showed post baseline &gt; ULN in 26.1% of patients treated with Stivarga and in 15.1% of patients receiving placebo.
U dva placebom kontrolirana ispitivanja faze III, testovi hormona koji stimulira štitnjaču (TSH) pokazali su naknadnu početnu vrijednost &gt; GGN u 26,1% bolesnika liječenih lijekom Stivarga i u 15,1% bolesnika koji su primali placebo.
In the two six-month studies, pre-bronchodilator FEV1 was significantly improved by 49 ml (primary endpoint, p &lt; 0.0001) beyond the bronchodilator effect of concomitant treatment with salmeterol in study M2-127 and by 80 ml (primary endpoint, p &lt; 0.0001) incremental to concomitant treatment with tiotropium in study M2-128.
U dva šestomjesečna ispitivanja predbronhodilatacijski FEV1 značajno je povećan za 49 ml (primarni ishod, p &lt; 0,0001) povrh bronhodilatacijskog učinka istodobnog liječenja salmeterolom u ispitivanju M2-127, te za 80 ml (primarni ishod, p &lt; 0,0001) dodatno na istodobno liječenje tiotropijem u ispitivanju M2-128.
In the urine, unchanged ataluren and the acyl glucuronide metabolite account for &lt; 1% and 49%, respectively, of the administered dose.
U urinu, neizmijenjeni ataluren čini &lt; 1%, a metabolit acil glukuronida 49% primijenjene doze.
In the week 96 efficacy analysis, the virologic response rate [confirmed undetectable viral load ( &lt; 50 HIV-1 RNA copies/ml)] was evaluated in patients receiving rilpivirine 25 mg once daily in addition to a BR versus patients receiving efavirenz 600 mg once daily in addition to a BR.
Stopa virološkog odgovora [potvrđeno nemjerljivo virusno opterećenje ( &lt; 50 HIV-1 RNK kopija/ml)] procijenjena je u 96. tjednu analize djelotvornosti u bolesnika koji su primali rilpivirin u dozi od 25 mg jedanput dnevno uz prateće liječenje, u usporedbi s bolesnicima koji su primali efavirenz u dozi od 600 mg jedanput dnevno uz prateće liječenje.
In these patients it is recommended that an electrocardiogram (ECG) is recorded before initiation of treatment with Trobalt and in those with a corrected QT interval &gt; 440ms at baseline, an ECG should be recorded on reaching the maintenance dose.
Prije započinjanja terapije lijekom Trobalt, kod navedenih bolesnika preporučuje se snimiti elektrokardiogram (EKG), a u onih s početnim korigiranim QT intervalom &gt; 440 ms treba snimiti EKG i nakon postizanja doze održavanja.
In these patients, non-renal events were generally comparable between patients with renal impairment and those without renal impairment, except a &gt; 10% higher incidence in dehydration (all grades) was noted (see section 4.4).
U tih su bolesnika događaji nevezani uz bubrege u načelu bili usporedivi između bolesnika s oštećenjem bubrežne funkcije i onih s normalnom bubrežnom funkcijom, izuzevši &gt; 10% veću incidenciju dehidracije (svih stupnjeva) (vidjeti dio 4.4).
In this open-label study, 443 patients already on an antiviral regimen containing Viramune 200 mg immediate-release twice daily with HIV-1 RNA &lt; 50 copies/ml were randomised in a 2:1 ratio to Viramune 400 mg prolonged- release once daily or Viramune 200 mg immediate-release twice daily.
U ovom otvorenom ispitivanju, 443 bolesnika na antivirusnom režimu Viramuneom 200 mg s trenutnim oslobađanjem dvaput dnevno s HIV-1 RNK &lt; 50 kopija/ml bili su randomizirani u omjeru 2:1 s obzirom na Viramune 400 mg s produljenim oslobađanjem jednom dnevno ili Viramune 200 mg s trenutnim oslobađanjem dvaput dnevno.
In this patient population, the most common adverse reactions ( &gt; 10%) with pembrolizumab were fatigue (24%), rash (19%), pruritus (18%), diarrhoea (12%), nausea (11%) and arthralgia (10%).
U toj su populaciji bolesnika najčešće nuspojave ( &gt; 10%) kod primjene pembrolizumaba bile umor (24%), osip (19%), pruritus (18%), proljev (12%), mučnina (11%) i artralgija (10%).
In this retrospective analysis, the superiority of Glivec over IFN+Ara-C in overall survival was demonstrated (p &lt; 0.001); within 42 months, 47 (8.5%) Glivec patients and 63 (19.4%) IFN+Ara-C patients had died.
U toj retrospektivnoj analizi pokazana je superiornost Gliveca nad INF+Ara-C-om u ukupnom preživljenju (p &lt; 0,001); unutar 42 mjeseca, umrlo je 47 (8,5%) bolesnika na Glivecu i 63 (19,4%) bolesnika na INF+Ara-C-u.
In this retrospective analysis, the superiority of imatinib over IFN+Ara-C in overall survival was demonstrated (p &lt; 0.001); within 42 months, 47 (8.5%) imatinib patients and 63 (19.4%) IFN+Ara-C patients had died.
U toj retrospektivnoj analizi pokazana je superiornost imatiniba nad IFN+Ara-C-om u ukupnom preživljenju (p &lt; 0,001); unutar 42 mjeseca, umrlo je 47 (8,5%) bolesnika na imatinibu i 63 (19,4%) bolesnika na IFN+Ara-C-u.
In this section, the following categories of frequency have been used: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
U ovom dijelu za prikaz nuspojava prema učestalosti korišteni su sljedeći kriteriji: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
In this section, the following categories of frequency have been used: very common (1/10), common (1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
U ovom dijelu, za prikaz nuspojava prema učestalosti korišteni su sljedeći kriteriji: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged &gt; 65 years compared with those less than 65 years (9.7% compared to 4.0%).
U ovom ispitivanju, u bolesnika koji su primali pioglitazon i inzulin zabilježen je veći postotak bolesnika sa zatajenjem srca u skupini bolesnika u dobi od ≥65 godina u odnosu na one mlađe od 65 godina (9,7% u odnosu na 4,0%).
In this study, 10 patients experienced elevations in AST and/or ALT &gt; 3 x ULN (see Table 6).
U ovom ispitivanju u 10 bolesnika došlo je do povišenja AST i/ili ALT &gt; 3 x GGN (vidjeti Tablica 6).
In this study, 2 patients treated with Epclusa for 12 or 24 weeks without ribavirin had emergent NS5B S282T at low levels ( &lt; 5%) along with L159F.
U ovom su ispitivanju dva bolesnika liječenja lijekom Epclusa tijekom 12 ili 24 tjedna bez ribavirina imala pojavu NS5B S282T pri niskim razinama ( &lt; 5 %) uz L159F.
In this study, PR interval of &gt; 200 msec was also observed in 40% and 47% of subjects receiving Invirase/ritonavir 1000/100 mg twice daily and 1500/100 mg twice daily, respectively, on Day 3.
U ovom je ispitivanju trećeg dana opažen i PR-interval &gt; 200 ms u 40% ispitanika koji su primali lijekove Invirase/ritonavir u dozi od 1000/100 mg dvaput na dan te u 47% ispitanika koji su te lijekove primali u dozi od 1500/100 mg dvaput na dan.
In this study, the overall population showed a benefit for the primary PFS end-point (HR= 0.71 p &lt; 0.0001) and the secondary OS end-point (HR= 0.81 p=0.0088).
U ovom je ispitivanju ukupna populacija ostvarila korist s obzirom na PFS kao primarnu mjeru ishoda (HR = 0,71, p &lt; 0,0001) i OS kao sekundarnu mjeru ishoda (HR = 0,81, p = 0,0088).
In this subgroup ADENURIC achieved the primary efficacy endpoint (sUA &lt; 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0 % in the placebo groups.
U ovoj podskupini ADENURIC je postigao primarni ishod djelotvornosti kod 41% (80 mg jednom dnevno), 48% (120 mg jednom dnevno) i 66% (240 mg dnevno) bolesnika, u usporedbi s 9% u skupini koja je primala alopurinol 300 mg/100 mg jednom dnevno i 0% u skupini koja je primala placebo.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: &lt; 20 kg, 20 - 40 kg, and &gt; 40 kg.
U ovom su se ispitivanju udarna doza i doza održavanja leflunomida zasnivale na 3 kategorije tjelesne težine: &lt; 20 kg, 20 - 40 kg i &gt; 40 kg.
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: &lt; 20 kg, 20-40 kg, and &gt; 40 kg.
U ovom su se ispitivanju udarna doza i doza održavanja leflunomida zasnivale na 3 kategorije tjelesne težine: &lt; 20 kg, 20-40 kg i &gt; 40 kg.
In three of four patients the change in the sweat chloride test was &lt; 5 mmol/L and this group did not demonstrate a clinically relevant improvement in FEV1 after 8 weeks of treatment.
U tri od četiri bolesnika promjena rezultata testa koncentracije klorida u znoju iznosila je &lt; 5 mmol/l i ta skupina nije pokazala klinički važno poboljšanje vrijednosti FEV1 nakon 8 tjedana liječenja.
In TORCH, older patients, patients with a lower body mass index ( &lt; 25 kg/m2) and patients with very severe disease (FEV1 &lt; 30% predicted) were at greatest risk of developing pneumonia regardless of treatment.
U ispitivanju TORCH, stariji bolesnici, bolesnici s nižim indeksom tjelesne mase ( &lt; 25 kg/m2) i bolesnici s jako teškom bolešću (FEV1 &lt; 30% predviđenog) imali su najveći rizik od razvoja pneumonije bez obzira na liječenje.
In TRA 2°P - TIMI 50, in vorapaxar- treated patients, including those with history of stroke, a higher rate of ICH was observed in patients weighing &lt; 60 kg compared to patients weighing ≥60 kg.
Među bolesnicima liječenima vorapaksarom u ispitivanju TRA 2ºP - TIMI 50, uključujući one s moždanim udarom u anamnezi, u bolesnika tjelesne težine &lt; 60 kg primijećena je viša stopa intrakranijalnog krvarenja nego u bolesnika tjelesne težine ≥60 kg.
In treatment-naïve MRCC patients receiving IFN-, six (2%) venous thromboembolic events occurred; one patient ( &lt; 1%) experienced a Grade 3 DVT and five patients (1%) had pulmonary embolisms, all with Grade 4.
U prethodno neliječenih bolesnika koji su za liječenje MRCC-a primali IFN-α zabilježeno je šest (2%) venskih tromboembolijskih događaja; jedan je bolesnik ( &lt; 1%) dobio duboku vensku trombozu stupnja 3, dok je u pet bolesnika (1%) došlo do plućne embolije, u svih stupnja 4.